Table 1.
Baseline characteristics
| cHL | DLBCL | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | No maintenance | Pembro maintenance | p- | No maintenance | Pembro maintenance | p- | |||
| n = | n = 31 (22) | n = 30 (21) | n = 54 (38) | n = 29 (20) | |||||
| Male | 89 | 19 (61) | 16 (53) | 0.61 ‡ | 33 (61) | 21 (72) | 0.34 ‡ | ||
| Age at ASCT | 0.97 † | 0.11 † | |||||||
| Median (range) | 52 | 32 (21 – 63) | 33 (20 – 69) | 60 (22 – 77) | 57 (22 – 76) | ||||
| Histology | 0.55 ‡ | 0.09 ‡ | |||||||
| cHL NOS | 32 | 2 (6) | 3 (10) | - | - | ||||
| Nodular Sclerosis | 23 | 27 (87) | 23 (77) | - | - | ||||
| Mixed Cellularity | 6 (4) | 2 (6) | 4 (13) | - | - | ||||
| DLBCL NOS | 56 | - | - | 39 (72) | 17 (59) | ||||
| TIL | 17 | - | - | 12 (22) | 5 (17) | ||||
| PMBL | 7 (5) | - | - | 2 (4) | 5 (17) | ||||
| TCHR | 3 (2) | - | - | 1 (2) | 2 (7) | ||||
| Number of systemic treatments prior to ASCT | 0.75 ‡ | 0.00 | |||||||
| Median (range) | 2 (1 – | 2 (1 – 5) | 2 (2 – 3) | 2 (2 – 3) | 2 (2 – 3) | ||||
| <= 2 | 115 | 24 (77) | 25 (83) | 48 (89) | 18 (62) | ||||
| 3 or more | 29 | 7 (23) | 5 (17) | 6 (11) | 11 (38) | ||||
| Primary refractory to first-line treatment | 0.31 ‡ | > | |||||||
| Yes | 53 | 13 (42) | 17 (57) | 15 (28) | 8 (28) | ||||
| Disease status at ASCT | 0.47 ‡ | 0.32 ‡ | |||||||
| CR | 114 | 25 (81) | 27 (90) | 40 (74) | 18 (62) | ||||
| PR | 23 | 6 (19) | 3 (10) | 14 (26) | 11 (38) | ||||
| Post-ASCT peripheral blood samples per patient | < | < | |||||||
| Median (range) | 5 (1 – | 4 (1 – 8) | 8 (1 – 8) | 3 (1 – 8) | 8 (1 – 8) | ||||
ASCT = auto ogous stem cell transplantation; cHL = classical Hodgkin lymphoma; DLBCL = diffuse large B-cell lymphoma; pembro = pembrolizumab; NOS = not other specified; TIL = transformed indolent lymphoma; PMBL = primary mediastinal B-cell lymphoma; TCHR = T cell histiocyte rich large B-cell lymphoma; CR = complete response; PR = partial response
‡
Fisher’s exact test
†
Wilcoxon rank-sum test